FDA Moves On Novartis Gene Therapy May Be Good For Kite Pharma – Barron’s
Barron’s |
FDA Moves On Novartis Gene Therapy May Be Good For Kite Pharma
Barron’s A Food And Drug Administration panel is expected to meet tomorrow to discuss Novartis's (NVS) experimental gene therapy drug, a move that could be good news for Kite Pharma (KITE), according to Canaccord Genuity. Illustration: Getty Images/iStockphoto. |
